COMMON STOCK PURCHASE WARRANT To Purchase n Shares of Common Stock of GENEREX BIOTECHNOLOGY CORPORATIONGenerex Biotechnology Corp • October 16th, 2006 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, n (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth (5th) anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to n shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
6% SECURED CONVERTIBLE DEBENTURE DUE MAY 28, 2007Generex Biotechnology Corp • October 16th, 2006 • Pharmaceutical preparations • New York
THIS DEBENTURE of Generex Biotechnology Company, a Delaware corporation, having a principal place of business at 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J2G2 (the “Company”), is designated as its 6% Convertible Debenture, due May 28, 2007 (the “Debenture”).
COMMON STOCK PURCHASE WARRANT To Purchase 800,000 Shares of Common Stock of GENEREX BIOTECHNOLOGY CORPORATIONSecurities Purchase Agreement • October 16th, 2006 • Generex Biotechnology Corp • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, n (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Generex Biotechnology Corporation, a Delaware corporation (the “Company”), up to 800,000 shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REDACTED - AS FILED THE MARKED PORTIONS OF THIS CLINICAL SUPPLY AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT CARDINAL HEALTH CLINICAL SUPPLY AGREEMENTClinical Supply Agreement • October 16th, 2006 • Generex Biotechnology Corp • Pharmaceutical preparations • Ohio
This Clinical Supply Agreement (“Agreement”) is made as of this ___day of September, 2006 (“Effective Date”), by and between Generex Biotechnology Corporation, a Delaware corporation, with a place of business at 33 Harbour Square, Toronto, ON, Canada M5J 2G2 (hereinafter “Client”) and Cardinal Health PTS, LLC, a Delaware limited liability company, with a place of business at 160 Cardinal Health Way, Morrisville, NC 27560 (hereinafter “Cardinal Health”).
